Q-omics provides the consensus-scored NPIPB3 profile across patient tissues and cancer cell-line models. NPIPB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NPIPB3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NPIPB3 RNA expression shows 18,700 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where NPIPB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB3 survival associations across molecular data types. NPIPB3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB3 RNA expression–survival associations across cancer types. High NPIPB3 expression shows unfavorable associations in KIRC, ACC, PRAD and LGG, but favorable associations in BLCA and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for NPIPB3 RNA expression.
This table summarizes NPIPB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB3 shows higher tumor expression in KIRC, KIRP, COAD, HNSC, LIHC and CHOL. The KIRC box plot shows higher NPIPB3 RNA expression in tumor versus normal tissue (log2 FC = +0.341, t-test p < 0.001).
This table shows molecular features associated with NPIPB3 in patient tissues and cancer cell lines. In patient samples, NPIPB3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
